natgillin/translations-raw huggingface dataset:
The compound for the use of claim 9, wherein the phosphate binder is sevelamer, sevelamer carbonate, or sevelamer hydrochloride. 
Spoj za uporabu sukladno zahtjevu 9, pri čemu je fosfatno vezivo sevelamer, sevelamer karbonat ili sevelamer hidroklorid.
Public sanitary device as claimed in claim 1, wherein the housing comprises two or more walk-in positions, wherein at least one of the walk-in positions (20) is provided with the door and at least one of the walk-in positions (30) is not provided with the door. 
Javni sanitarni uređaj prema zahtjevu 1, pri čemu kućište ima dva ili više položaja u ravnini poda, pri čemu je najmanje jedan od položaja (20) u ravnini poda opremljen vratima i najmanje jedan od položaja (30) u ravnini poda nije opremljen vratima.
Public sanitary device as claimed in claim 4 or 5, wherein the door is mounted in a rail (45) extending along an inner surface of the housing. 
Javni sanitarni uređaj prema zahtjevu 4 ili 5, pri čemu su vrata montirana u vodilici (45) koja se pruža duž unutrašnje površine kućišta.
Public sanitary device as claimed in claim 10, wherein the rods are hydraulic cylinders, preferably telescopic cylinders. 
Javni sanitarni uređaj prema zahtjevu 10, pri čemu su poluge hidraulični cilindri, a prvenstveno teleskopski cilindri.
Process according to claim 1, wherein mixing is performed shortly after whipping of said fermented dairy base and/or said cream, preferably by continuous dynamic mixing. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se miješanje provodi ubrzo nakon tučenja navedene fermentirane mliječne baze i/ili navedenog vrhnja, po mogućnost kontinuiranim dinamičnim miješanjem.
Process according to claim 1 or 2, wherein the cream is pasteurised. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je vrhnje pasterizirano.
Process according to claim 1 or 2, wherein the cream further comprises a stabiliser composition and is sterilised. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što vrhnje dodatno sadrži stabilizirajući pripravak i sterilizirano je.
The method of claim 1, wherein the pharmaceutically acceptable salt is A method for treating hyperphosphatemia in a subject in need thereof comprising administering to the subject an effective amount of the compound or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu je farmaceutski prihvatljiva sol Spoj za uporabu u liječenju hiperfosfatemije kod subjekta, pri čemu se odgovarajuća doza spoja daje subjektu i pri čemu je spoj ili njegova farmaceutski prihvatljiva sol.
The method of claim 3, wherein the pharmaceutically acceptable salt is 
Spoj za uporabu sukladno zahtjevu 3, pri čemu je farmaceutski prihvatljiva sol
The method of claim 6, wherein the phosphate binder is sevelamer, sevelamer carbonate, or sevelamer hydrochloride. 
Spoj za uporabu sukladno zahtjevu 6, pri čemu je fosfatno vezivo sevelamer, sevelamer karbonat ili sevelamer hidroklorid.
A double stranded RNA according to any one of claims 1 or claim 2, wherein the first RNA sequence and second RNA sequence are selected from the group consisting of the combinations of SEQ ID NO. 
Dvolančana RNA u skladu s bilo kojim od patentnih zahtjeva 1 ili patentnim zahtjevom 2, naznačena time što se prvi RNA slijed i drugi RNA slijed bira iz skupine koju čine kombinacije SEQ ID NO.
An expression cassette according to claim 7, wherein the expression cassette comprises the PGK promoter, a CMV promoter, a neurospecific promoter or a CBA promoter. 
Ekspresijska kaseta u skladu s patentnim zahtjevom 7, naznačena time što ekspresijska kaseta sadrži PGK promotor, CMV promotor, neurospecifični promotor ili CBA promotor.
is a bicyclic sugar; or 
je biciklični šećer; i/ili
The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of SEQ ID NO: 12, and wherein the modified oligonucleotide comprises: 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 20 povezanih nukleozida sa sekvencom nukleobaza koja čini SEQ ID NO: 3 i gdje modificirani oligonukleotid sadrži:
The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of any one of SEQ ID NOs: 13-19, and wherein the modified oligonucleotide comprises: 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 20 povezanih nukleozida sa sekvencom nukleobaza koja čini SEQ ID NO: 4 i gdje modificirani oligonukleotid sadrži:
the conjugate group comprises: 
i konjugatna grupa sadrži:
The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides with the nucleobase sequence of SEQ ID NO: 87, wherein the modified oligonucleotide comprises: 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 20 povezanih nukleozida sa sekvencom nukleobaza koja čini SEQ ID NO: 4 i gdje modificirani oligonukleotid sadrži:
A compound comprising a peptide wherein the peptide comprises the amino acid sequence: 
Spoj koji sadrži peptid i konjugiranu skupinu, pri čemu peptid sadrži sekvencu aminokiseline:
The compound of claim 1, wherein the peptide comprises a contiguous sequence of D-amino acid residues. 
Spoj za uporabu prema zahtjevu 1, naznačen time što peptid sadrži susjednu sekvencu ostataka D-aminokiselina.
The compound of any one of claims 1-4, wherein the peptide is 8 to 9, 8 to 10 or 8 to 11 amino acids in length. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što peptid ima duljinu od 8 do 15 amino kiselina.
a targeter-RNA comprising a nucleotide sequence that is complementary to a target sequence of a target DNA molecule, and 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran slijedu u ciljanoj DNA, i
a targeter-RNA comprising a nucleotide sequence that is complementary to a target sequence of a target DNA molecule, and 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
Monitoring and control system according to claim 5, further comprising at least one isolator device (914, 930, 944; 1930) connected in series between the at least one measuring transducer (910, 960; 1960) and the controller (900), wherein the isolator device electrically isolates the measuring transducers from the controller, wherein, in particular, the number of isolator devices is equal or less than the number of measuring transducers. 
Sustav za nadgledanje i upravljanje prema patentnom zahtjevu 4, naznačen time što nadalje sadrži najmanje jedan izolacijski uređaj (914, 930, 944; 1930) spojen u nizu između najmanje jednog mjernog pretvornika (910, 960; 1960) i kontrolera (900), pri čemu izolacijski uređaj električno izolira mjerne pretvornike od kontrolera, pri čemu je, naročito, broj izolacijskih uređaja jednak ili manji od broja mjernih pretvornika.
Monitoring and control system according to claim 5 or 6, further comprising at least one isolated power supply (918, 948; 1930) for providing power to the multiplexer and/or the at least one measuring transducer (910, 960; 1960), wherein in particular the number of isolated power supplies is equal or less than the number of measuring transducers. 
Sustav za nadgledanje i upravljanje prema patentnom zahtjevu 4 ili 5, naznačen time što nadalje sadrži najmanje jedan izolirani izvor napajanja (918, 948; 1930) za osiguravanje napajanja za multiplekser i/ili najmanje jedan mjerni pretvornik (910, 960; 1960), pri čemu je naročito broj izoliranih izvora napajanja jednak ili manji od broja mjernih pretvornika.
Monitoring and control system according to one of the preceding claims, wherein at least one, in particular each, measuring transducer is an analogue digital converter (910, 960; 1960) for converting a voltage applied to the input terminal to a digital value with respect to the respective reference voltage input and/or wherein the regulating devices (100, 200, 800; 1100) are switches. 
Sustav za nadgledanje i upravljanje prema jednom od prethodnih patentnih zahtjeva, naznačen time što je najmanje jedan, te naročito svaki, mjerni pretvornik analogno digitalni pretvornik (910, 960; 1960) za pretvaranje napona koji se primjenjuje na ulazni priključak u digitalnu vrijednost u odnosu na odgovarajući referentni ulazni napon i/ili pri čemu regulacijski uređaji (100, 200, 800; 1100) su prekidači.
Monitoring and control system according to one of the preceding claims, wherein the safety critical loads (3) are signalling lamps and/or traffic lights, in particular for a railway. 
Sustav za nadgledanje i upravljanje prema jednom od prethodnih patentnih zahtjeva, naznačen time što su sigurnosna kritična opterećenja (3) signalne lampe i/ili semafori, naročito za željeznicu.
Traffic light system, in particular for trains, comprising the monitoring and control system according to one of the preceding claims. 
Sustav semafora, naročito za vlakove, naznačen time što sadrži sustav za nadgledanje i upravljanje prema jednom od prethodnih patentnih zahtjeva.
calculating the output voltage (Vout) provided to the safety critical load based on at least the first voltage value and the second voltage value, and, in particular the third voltage value. 
izračunavanje izlaznog napona (Vout) koji se daje sigurnosnom kritičnom opterećenju na temelju najmanje prve vrijednosti napona i druge vrijednosti napona, te naročito treće vrijednosti napona.
a targeter-RNA that is capable of hybridizing with a target sequence in a target DNA molecule, and 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
A compound represented by general formula [1]: wherein 
Spoj predstavljen općom formulom [1]:
represents a hydrogen atom or an optionally substituted C1-6 alkyl group; 
predstavlja atom vodika ili po izboru supstituiranu C1-6 alkilnu skupinu;
represents an oxygen atom or a sulfur atom; and 
predstavlja atom kisika ili atom sumpora; i
The compound, pharmaceutical salt or pharmaceutical composition for the use according to claim 14, wherein the disease or the disorder is psoriasis, psoriatic arthritis, rheumatoid arthritis, allergic asthma, severe asthma, steroid resistant asthma, COPD, systemic lupus erythematous, primary immunodeficiency syndrome or cancer. 
Spoj, farmaceutska sol ili farmaceutska kompozicija za primjenu prema patentnom zahtjevu 14, gdje bolest ili poremećaj je psorijaza, psorijazni artritis, reumatoidni artritis, alergijska astma, teška astma, steroid rezistentna astma, COPD, sistemski eritemski lupus, sindrom primarne imunodeficijencije ili rak.
A pharmaceutical composition for prolonged release of trimetazidine, comprising: 
Farmaceutski pripravak s produljenim otpuštanjem trimetazidina, pri čemu:
The composition according to claim 1, wherein the level of in vitro dissolution of the composition is from 8% to 28% of the trimetazidine released by 4 hours and from 37% to 57% of the trimetazidine released by 8 hours and more than 75% of the trimetazidine released by 24 hours and is selected so that the therapeutically efficacious plasma concentration of trimetazidine obtained in vivo is prolonged over 24 hours following administration of the composition. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time, da je razina in vitro otapanja pripravka od 8 % do 28 % trimetazidina otpuštenog tijekom 4 sata i od 37 % do 57 % trimetazidina otpuštenog tijekom 8 sati i više od 75 % trimetazidina otpuštenog tijekom 24 sata, tako da se terapijski djelotvorna koncentracija trimetazidina u plazmi, dobivena in vivo, produljuje tijekom 24 sata nakon primjene farmaceutskog pripravka.
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the second articulated telescopic segment (9) is longitudinally actuated by a fourth hydraulic cylinder (13). 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što četvrti hidraulični cilindar (13) uzdužno aktuira drugi uzglobljeni teleskopski segment (9).
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the tool attached to the free end of the third articulated telescopic segment (11) is defined by a metal detector (17). 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što je alat pričvršćen na slobodni kraj trećeg uzglobljenog teleskopskog segmenta (11) definiran detektorom metala (17).
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claims 2 and 3, characterised in that the fourth hydraulic cylinder for longitudinal adjustment of the second articulated telescopic segment and the fifth hydraulic cylinder for longitudinal adjustment of the third telescopic articulated segment, are integrated and protected inside a tubular structure. 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevima 2 i 3, naznačena time što su četvrti hidraulični cilindar za uzdužno podešavanje drugog uzglobljenog teleskopskog segmenta i peti hidraulični cilindar za uzdužno podešavanje trećeg teleskopskog uzglobljenog segmenta, integrirani i zaštićeni unutar cjevaste strukture.
represents N and X1 represents CH, n represents an integer equal to 2; and each R2 represents C1-4alkoxy, for example CH3O-; R3 represents hydroxyC1-6alkyl, haloC1-6alkyl, C1-6alkyl substituted with R9, C1-6alkyl substituted with -NR10R11, C1-6alkoxyC1-6alkyl, C2-6alkynyl; Y represents -E-D wheren E represents a bond and D represents pyrazolyl substituted with C1-6alkyl; R10 and R11 represent hydrogen or C1-6alkyl; R9 represents an optionally substituted 5 membered aromatic heterocycle, such as for example optionally substituted imidazolyl; or 
predstavlja N, a X1 predstavlja CH, n predstavlja cijeli broj 2; i svaki R2 predstavlja C1-4-alkoksi, na primjer CH3 O; R3 predstavlja hidroksiC1-6alkil, halogenC1-6 alkil, C1-6 alkil supstituiran s R9, C1-6 alkil supstituiran s -NR10 R11, C1-6 alkoksiC 1-6alkil, C2-6 alkinil; Y predstavlja -E-D gdje E predstavlja vezu i D R3 predstavlja pirazolil supstituiran sa C1-6alkilom; R10 i R11 predstavljaju vodik ili C1-6 alkil; R9 predstavlja ponekad supstituirani 5-eročlani aromatski heterocikl, kao što je na primjer izborno supstituirani imidazolil; ili
use in therapy; or 
uporaba u terapiji; ili
use in the prophylaxis or treatment of a disease state or condition mediated by a FGFR kinase; or 
uporaba u profilaksi ili liječenju bolesnog stanja ili stanja uzrokovanog FGFR kinazom; ili
use in the prophylaxis or treatment of cancer; or 
uporaba u profilaksi ili liječenju raka; ili
use in the treatment of cancer wherein the cancer is selected from prostate cancer, bladder cancer, lung cancer such as NSCLC, breast cancer, gastric cancer, and liver cancer; or 
uporaba u liječenju karcinoma, gdje je karcinom odabran od karcinoma prostate, karcinoma mjehura, pluća karcinom kao što je NSCLC, karcinom dojke, karcinom želuca i karcinom jetre; ili
use in the treatment of cancer wherein the cancer is selected from multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma; or 
upotreba u liječenju karcinoma, pri čemu je karcinom odabran od multiplog mijeloma, mijeloproliferativnog poremećaji, karcinom endometrija, karcinom prostate, karcinom mjehura, karcinom pluća, karcinom jajnika, karcinom dojke, karcinom želuca, kolorektalni karcinom i karcinom peroralnih skvamoznih stanica; ili
use in the treatment of cancer wherein the cancer is selected from lung cancer, in particular NSCLC, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, prostate cancer; or 
upotreba u liječenju karcinoma, gdje je karcinom odabran od karcinoma pluća, posebno NSCLC, karcinom pločastih stanica, karcinom jetre, karcinom bubrega, karcinom dojke, karcinom debelog crijeva, kolorektalni karcinom, karcinom prostate; ili
use in the treatment of cancer wherein the cancer is bladder cancer; or 
uporaba u liječenju karcinoma, gdje je karcinom karcinom mokraćnog mjehura; ili
use in the treatment of cancer wherein the cancer is bladder cancer with a FGFR3 chromosomal translocation; or 
uporaba u liječenju karcinoma, gdje je karcinom karcinom mokraćnog mjehura s FGFR3 kromosomskom translokacijom; ili
use in the treatment of cancer wherein the cancer is bladder cancer with a FGFR3 point mutation; or 
uporaba u liječenju karcinoma, gdje je karcinom karcinom mokraćnog mjehura s točkastom mutacijom FGFR3; ili
use in the treatment of cancer wherein the cancer is a tumour with a mutant of FGFR1, FGFR2, FGFR3 or FGFR4; or (xiii) use in the treatment of cancer wherein the cancer is a tumour with a gain-of-function mutant of FGFR2 or FGFR3; or 
uporaba u liječenju karcinoma, gdje je karcinom tumor s mutantom FGFR1, FGFR2, FGFR3 ili FGFR4; ili (xiii) uporaba u liječenju karcinoma, pri čemu je karcinom tumor s mutantom FGFR2 s pojačanom funkcijom ili FGFR3; ili
wherein said organic solvent used in said organic extraction (OE) is dichloromethane (CH2Cl2, DCM). wherein: 
pri čemu navedeno organsko otapalo koje se koristi u navedenoj organskoj ekstrakciji (OE) jest diklorometan (CH2Cl2, DCM).
A liquid pharmaceutical composition according to any one of claims 1 to 12 for use in the treatment or prevention of a disease or condition selected from asthma, allergic asthma, hay fever, allergic rhinitis, bronchitis, emphysema, bronchiectasis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), steroid resistant asthma, severe asthma, paediatric asthma, cystic fibrosis, lung fibrosis, pulmonary fibrosis, interstitial lung disease, skin disorders, atopic dermatitis, psoriasis, ocular inflammation, cerebral ischaemia, inflammatory diseases and auto-immune diseases, preferably wherein the disease or condition is chronic obstructive pulmonary disease (COPD). 
Tekući farmaceutski pripravak prema bilo kojem patentnom zahtjevu od 1 do 11 za primjenu u liječenju ili sprječavanju bolesti ili stanja odabranog iz astme, alergijske astme, peludne groznice, alergijskog rinitisa, bronhitisa, emfizema, bronhiektazije, kronične opstruktivne plućne bolesti (KOPB), sindroma respiratornog distresa odraslih (ARDS), astme otporne na kortikosteroide, teške astme, pedijatrijske astme, cistične fibroze, plućne fibroze, intersticijske bolesti pluća, kožnih poremećaja, atopijskog dermatitisa, psorijaze, upale oka, cerebralne ishemije, upalnih bolesti i autoimunih bolesti. Tekući farmaceutski pripravak za primjenu prema patentnom zahtjevu 14, naznačen time, što je bolest ili stanje kronična opstruktivna bolest plućna bolest (KOPB).
The solid pharmaceutical composition according to claim 1, comprising two lipophilic active compounds, preferably fenofibrate and atorvastatin, both positioned in intimate contact with the polymeric matrix, wherein said polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the lipophilic drugs, said matrix being preferably formed by two polymers, one of the polymers is an amphiphilic polymer, preferably Poloxamer 407, and the other polymer is a hydrophilic polymer, preferably sodium carboxymethylcellulose, sodium alginate or chitosan. 
Kruti farmaceutski pripravak prema zahtjevu 1, koji sadrži dva lipofilna aktivna spoja, poželjno fenofibrat i atorvastatin, oba smještena u bliskom kontaktu s polimernom matricom, pri čemu navedena polimerna matrica nije poprečno povezana i ne dolazi do kovalentne interakcije između dva ili više polimera i između polimera i lipofilnih lijekova, navedena je matrica poželjno načinjena od dva polimera, jedan od polimera je amfifilni polimer, poželjno Poloksamer 407, a drugi polimer je hidrofilni polimer, poželjno natrijeva karboksimetilceluloza, natrijev alginat ili hitozan.
The solid composition according to claim 1, which is a nutraceutical composition comprising at least one lipophilic nutraceutical interwoven with a polymeric matrix formed by two or more polymers, wherein said polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the at least one lipophilic nutraceutical, further comprising one or more nutraceuticals, nutritional agents, acceptable carriers, excipients or a mixture thereof. 
Kruti pripravak prema zahtjevu 1, koji je nutraceutski pripravak koji sadrži barem jedan lipofilni nutraceutski proizvod koji se isprepliće s polimernom matricom koja se sastoji od dva ili više polimera, pri čemu navedena polimerna matrica nije poprečno povezana i ne dolazi do kovalentne interakcije između dva ili više polimera i između polimera i najmanje jednog lipofilnog nutraceutskog proizvoda, koji nadalje sadrži jedan ili više nutraceutskih proizvoda, prehrambenih agenasa, prihvatljivih nosača, pomoćnih tvari ili njihove smjese.
The solid pharmaceutical composition according to any one of claims 1 to 6, which is designed for release of the lipophilic drug either in the gut or in the intestine, preferably a composition that forms colloidal nanodispersion upon contact with biological fluids with pH 6-8 that corresponds to the pH of intestinal fluids. 
Kruti farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, koji je namijenjen za oslobađanje lipofilnog lijeka bilo u utrobi ili crijevima, poželjno pripravak koji tvori koloidnu nanodisperziju u kontaktu s biološkim tekućinama s pH 6-8 koji odgovara pH crijevnih tekućina.
drying the polymers-lipophilic active compound complex clear and homogeneous solution of (i) to form a dry powder; 
sušenje bistre i homogene otopine polimera-lipofilnog aktivnog spoja (i) za formiranje suhog praha;
wherein the aqueous solution has at least 50% by weight of water and the drying in step (ii) is carried out by spray drying. 
pri čemu vodenasta otopina ima najmanje 50% težinski vode i sušenje u koraku (ii) se provodi sušenjem raspršivanjem.
a cannabidiol (CBD) content that is greater than 5.0% by weight; 
sadržaj kanabidiola (CBD) koji je veći od 5,0%, težinski;
a tetrahydrocannabinol (THC) content that is at least 5.0% by weight; 
sadržaj tetrahidrokanabinola (THC) koji je najmanje 5,0%, težinski;
a terpene oil content greater than 1% by weight; 
sadržaj terpenskog ulja veći od 1%, težinski;
wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the inflorescence, wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on dry weight of the inflorescence; 
gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, a-felandrena, β-ocimena, karena, limonena, γ-terpinena, a-pinena, a-terpinena, β-pinena, fenhola, kamfena, a-terpineola, a-humulena, β-kariofilena, linaloola, kariofilen-oksida, te mircena u inflorescencijiama, gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi suhe težine inflorescencije;
The dry sinsemilla cannabis inflorescence of claim 1, wherein the terpene oil content is greater than 1.3% by weight. 
Suha inflorescencija besjemenog kanabisa u skladu s patentnim zahtjevom 1, naznačena time što je sadržaj terpenskog ulja veći od 1,3%, težinski.